Abstract
Background: Home care (HC) patients are characterized by a high level of complexity, which is reflected by the prevalence of multimorbidity and the correlated high drug consumption. This study assesses prevalence and factors associated with polypharmacy in a sample of HC patients in Europe. Methods: We conducted a cross-sectional analysis on 1873 HC patients from six European countries participating in the Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care (IBenC) project. Data were collected using the interResident Assessment Instrument (interRAI) instrument for HC. Polypharmacy status was categorized into three groups: non-polypharmacy (0–4 drugs), polypharmacy (5–9 drugs), and excessive polypharmacy (≥ 10 drugs). Multinomial logistic regressions were used to identify variables associated with polypharmacy and excessive polypharmacy. Results: Polypharmacy was observed in 730 (39.0%) HC patients and excessive polypharmacy in 433 (23.1%). As compared with non-polypharmacy, excessive polypharmacy was directly associated with chronic disease but also with female sex (odds ratio [OR] 1.58; 95% confidence interval [CI] 1.17–2.13), pain (OR 1.51; 95% CI 1.15–1.98), dyspnea (OR 1.37; 95% CI 1.01–1.89), and falls (OR 1.55; 95% CI 1.01–2.40). An inverse association with excessive polypharmacy was shown for age (OR 0.69; 95% CI 0.56–0.83). Conclusions: Polypharmacy and excessive polypharmacy are common among HC patients in Europe. Factors associated with polypharmacy status include not only co-morbidity but also specific symptoms and age.
| Original language | English |
|---|---|
| Pages (from-to) | 145-152 |
| Number of pages | 8 |
| Journal | Drugs and Aging |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Geriatrics and Gerontology
- Pharmacology (medical)
Cite this
Polypharmacy in Home Care in Europe : Cross-Sectional Data from the IBenC Study. / Giovannini, Silvia; van der Roest, Henriëtte G.; Carfì, Angelo; Finne-Soveri, Harriet; Garms-Homolová, Vjenka; Declercq, Anja; Jónsson, Pálmi V.; van Hout, Hein; Vetrano, Davide L.; Gravina, Ester Manes; Bernabei, Roberto; Onder, Graziano.
In: Drugs and Aging, Vol. 35, No. 2, 01.02.2018, p. 145-152.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Polypharmacy in Home Care in Europe
T2 - Cross-Sectional Data from the IBenC Study
AU - Giovannini, Silvia
AU - van der Roest, Henriëtte G.
AU - Carfì, Angelo
AU - Finne-Soveri, Harriet
AU - Garms-Homolová, Vjenka
AU - Declercq, Anja
AU - Jónsson, Pálmi V.
AU - van Hout, Hein
AU - Vetrano, Davide L.
AU - Gravina, Ester Manes
AU - Bernabei, Roberto
AU - Onder, Graziano
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background: Home care (HC) patients are characterized by a high level of complexity, which is reflected by the prevalence of multimorbidity and the correlated high drug consumption. This study assesses prevalence and factors associated with polypharmacy in a sample of HC patients in Europe. Methods: We conducted a cross-sectional analysis on 1873 HC patients from six European countries participating in the Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care (IBenC) project. Data were collected using the interResident Assessment Instrument (interRAI) instrument for HC. Polypharmacy status was categorized into three groups: non-polypharmacy (0–4 drugs), polypharmacy (5–9 drugs), and excessive polypharmacy (≥ 10 drugs). Multinomial logistic regressions were used to identify variables associated with polypharmacy and excessive polypharmacy. Results: Polypharmacy was observed in 730 (39.0%) HC patients and excessive polypharmacy in 433 (23.1%). As compared with non-polypharmacy, excessive polypharmacy was directly associated with chronic disease but also with female sex (odds ratio [OR] 1.58; 95% confidence interval [CI] 1.17–2.13), pain (OR 1.51; 95% CI 1.15–1.98), dyspnea (OR 1.37; 95% CI 1.01–1.89), and falls (OR 1.55; 95% CI 1.01–2.40). An inverse association with excessive polypharmacy was shown for age (OR 0.69; 95% CI 0.56–0.83). Conclusions: Polypharmacy and excessive polypharmacy are common among HC patients in Europe. Factors associated with polypharmacy status include not only co-morbidity but also specific symptoms and age.
AB - Background: Home care (HC) patients are characterized by a high level of complexity, which is reflected by the prevalence of multimorbidity and the correlated high drug consumption. This study assesses prevalence and factors associated with polypharmacy in a sample of HC patients in Europe. Methods: We conducted a cross-sectional analysis on 1873 HC patients from six European countries participating in the Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care (IBenC) project. Data were collected using the interResident Assessment Instrument (interRAI) instrument for HC. Polypharmacy status was categorized into three groups: non-polypharmacy (0–4 drugs), polypharmacy (5–9 drugs), and excessive polypharmacy (≥ 10 drugs). Multinomial logistic regressions were used to identify variables associated with polypharmacy and excessive polypharmacy. Results: Polypharmacy was observed in 730 (39.0%) HC patients and excessive polypharmacy in 433 (23.1%). As compared with non-polypharmacy, excessive polypharmacy was directly associated with chronic disease but also with female sex (odds ratio [OR] 1.58; 95% confidence interval [CI] 1.17–2.13), pain (OR 1.51; 95% CI 1.15–1.98), dyspnea (OR 1.37; 95% CI 1.01–1.89), and falls (OR 1.55; 95% CI 1.01–2.40). An inverse association with excessive polypharmacy was shown for age (OR 0.69; 95% CI 0.56–0.83). Conclusions: Polypharmacy and excessive polypharmacy are common among HC patients in Europe. Factors associated with polypharmacy status include not only co-morbidity but also specific symptoms and age.
UR - http://www.scopus.com/inward/record.url?scp=85041617509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041617509&partnerID=8YFLogxK
U2 - 10.1007/s40266-018-0521-y
DO - 10.1007/s40266-018-0521-y
M3 - Article
C2 - 29411310
AN - SCOPUS:85041617509
VL - 35
SP - 145
EP - 152
JO - Drugs and Aging
JF - Drugs and Aging
SN - 1170-229X
IS - 2
ER -